Osteosarcoma in Children Clinical Trial
— STARTosOfficial title:
Long-term Evaluation of the Quality of Life and the Functional Repercussions of Former Patients Treated With Orthopedic Surgery, With or Without Radiotherapy
NCT number | NCT04644913 |
Other study ID # | ICO |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | November 18, 2022 |
Est. completion date | January 29, 2023 |
Verified date | July 2023 |
Source | Institut Cancerologie de l'Ouest |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Surgery and radiation therapy play a major role in the treatment of bone and soft tissue tumors. Osteosarcomas, rhabdomyosarcomas, and Ewing tumors are the most common histologic types. Surgery may require multiple techniques and radiation therapy may be conformational, or more recently IMRT (Intensity Modulated Radiation Therapy). If surgery is possible, lower limb surgery is generally the recommended treatment, even if a poor functional result can be expected. The literature is very poor regarding the impact of radiotherapy on quality of life and functional results, mainly with the use of prosthetic materials. Tools such as the Toronto Extremity Salvage Score (TESS) are now available for self-assessment of functional outcomes. The presence of large cohorts such as FCCSS, COHOPER and SALTO facilitates these studies. The SF-36 is a short 36-question health questionnaire that consists of a generic, consistent, and easy-to-administer set of measures. These measures are based on self-report by patients and are now widely used by organizations managing the care of adult patients. The TESS Functional Questionnaire is a patient-completed self-questionnaire widely used for motor stimulation in patients with musculoskeletal tumors. This score is based on the definitions of handicap, impairment and handicap as documented by the World Health Organization (WHO). It includes 30 questions assessing overall function and daily activities. The final score varies from 0% to 100%, 100% being the best possible score. So far, several studies have reported the validation of TESS in Portuguese, Danish, Korean, Japanese and since this year in French. Indeed, the TESS questionnaire was validated in French by the study "Transcultural validation of TESS and MSTS questionnaires" promoted by the Nantes University Hospital.
Status | Completed |
Enrollment | 300 |
Est. completion date | January 29, 2023 |
Est. primary completion date | January 29, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: Patients from the French FCCSS or COHOPER or SALTO cohorts Adult patient (> 18 years old) when filling out the study questionnaires Patient treated for a bone tumor before the age of 18 Patient with a minimum follow-up of 5 years without cancer treatment (treated before 2014) Patient living in France and speaking French Exclusion Criteria: Patient with a 2nd cancer Patient who has already been approached by the Hospital de NANTES as part of the cross-cultural validation of the TESS questionnaire |
Country | Name | City | State |
---|---|---|---|
France | Institut de Canérologie de l'Ouest | Angers |
Lead Sponsor | Collaborator |
---|---|
Institut Cancerologie de l'Ouest |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The concordance of scores from the quality of life questionnaires: SF 36 and TESS | Scoring of questionnaires SF36 and TESS | 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03628209 -
Nivolumab or Nivolumab and Azacitidine in Patients With Recurrent, Resectable Osteosarcoma
|
Phase 1/Phase 2 | |
Completed |
NCT05794594 -
3D Printed Personalized Extendable Prosthesis
|
||
Suspended |
NCT05558280 -
Qarziba for Patients in Relapsed/Refractory High-grade Osteosarcoma
|
Phase 2 | |
Active, not recruiting |
NCT04803877 -
SARC038: Phase 2 Study of Regorafenib and Nivolumab in Osteosarcoma
|
Phase 2 | |
Not yet recruiting |
NCT06341712 -
Effects of Maintenance Cabozantinib+BSC Versus BSC in Children and AYA With Osteosarcoma
|
Phase 2 | |
Terminated |
NCT03139318 -
Phase I Clinical Trial of GRID Therapy in Pediatric Osteosarcoma of the Extremity
|
N/A | |
Recruiting |
NCT05107843 -
Integrated Clinical-radiological Analysis of Hypoxia Markers in Pediatric Osteosarcomas
|